Literature DB >> 18789721

Preparation and use of therapeutic antibodies primarily of human origin.

E Richard Stiehm1, Margaret A Keller, Girish N Vyas.   

Abstract

Therapeutic antibodies include polyclonal immunoglobulins isolated from regular or high-titered human plasma, sera from immunized animals, and monoclonal antibodies. This array of therapeutic antibodies is used for the prevention and treatment of many infectious diseases, antibody immunodeficiencies, autoimmune and inflammatory diseases, neurological disorders, and cancers. Polyclonal human immunoglobulins are available for intramuscular injection (IGIM), intravenous infusion (IGIV) and subcutaneous infusion (SCIG). We review these products and detail the therapeutic use of polyclonal human antibodies in the treatment of antibody immunodeficiencies, including their occasional local side effects (tenderness, sterile abscesses), minor systemic side effects (chills, muscle aches, malaise, headaches) and major side effects (aseptic meningitis, nephropathy, thrombosis).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789721     DOI: 10.1016/j.biologicals.2008.07.002

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  12 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

2.  Intravenous immunoglobulin in pediatrics: A review.

Authors:  A N Prasad; Sanjay Chaudhary
Journal:  Med J Armed Forces India       Date:  2013-08-06

Review 3.  Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

Authors:  Ewa Więsik-Szewczyk; Aleksandra Kucharczyk; Katarzyna Świerkocka; Elżbieta Rutkowska; Karina Jahnz-Różyk
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

4.  More than a headache: a case of cetuximab-induced aseptic meningitis.

Authors:  Devika Prasanna; Tarek Elrafei; Elaine Shum; Marianna Strakhan
Journal:  BMJ Case Rep       Date:  2015-05-12

Review 5.  Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.

Authors:  Fernando C Barros; Zulfiqar Ahmed Bhutta; Maneesh Batra; Thomas N Hansen; Cesar G Victora; Craig E Rubens
Journal:  BMC Pregnancy Childbirth       Date:  2010-02-23       Impact factor: 3.007

Review 6.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

7.  Separation of immunoglobulin G using aqueous biphasic systems composed of cholinium-based ionic liquids and poly(propylene glycol).

Authors:  Catarina C Ramalho; Catarina M S S Neves; Maria V Quental; João A P Coutinho; Mara G Freire
Journal:  J Chem Technol Biotechnol       Date:  2018-01-31       Impact factor: 3.174

8.  Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle.

Authors:  Akiko Sano; Hiroaki Matsushita; Hua Wu; Jin-An Jiao; Poothappillai Kasinathan; Eddie J Sullivan; Zhongde Wang; Yoshimi Kuroiwa
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

9.  Back to the future: recombinant polyclonal antibody therapeutics.

Authors:  Xian-Zhe Wang; Vincent W Coljee; Jennifer A Maynard
Journal:  Curr Opin Chem Eng       Date:  2013-11       Impact factor: 5.163

Review 10.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

Authors:  Hilal Ahmed Parray; Shivangi Shukla; Sweety Samal; Tripti Shrivastava; Shubbir Ahmed; Chandresh Sharma; Rajesh Kumar
Journal:  Int Immunopharmacol       Date:  2020-05-27       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.